We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$244M
1-Year Est. Return
80.12%
This Fund
S&P 500
This Quarter
Est. Return
-2.44%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$244M
AUM Growth
-$30.4M
(-11%)
Cap. Flow
-$7.85M
Cap. Flow
% of AUM
-3.22%
Top 10 Holdings %
Top 10 Hldgs %
67.25%
Holding
48
New
10
Increased
7
Reduced
9
Closed
7
Top Buys
| 1 |
Vaxcyte
PCVX
|
+$15.7M |
| 2 |
Vor Biopharma
VOR
|
+$9.87M |
| 3 |
Celldex Therapeutics
CLDX
|
+$9M |
| 4 |
Xeris Biopharma Holdings
XERS
|
+$7.43M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$7.17M |
Top Sells
| 1 |
ATYR
aTyr Pharma
ATYR
|
+$13.6M |
| 2 |
Cytokinetics
CYTK
|
+$12.4M |
| 3 |
CG Oncology
CGON
|
+$11.3M |
| 4 |
Replimune Group
REPL
|
+$10.8M |
| 5 |
DFTX
Definium Therapeutics
DFTX
|
+$10.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Delcath Systems
DCTH
$454M
| $30.6M | 12.55% |
3,300,389
| – | – |
|
|
2
Xeris Biopharma Holdings
XERS
$1.43B
| $18.7M | 7.68% |
3,231,700
+1,120,000
| +53% | +$7.43M |
|
3
Fennec Pharmaceuticals
FENC
$388M
| $17.9M | 7.33% |
2,908,201
+294,693
| +11% | +$2.28M |
|
4
Savara
SVRA
$1.17B
| $17.5M | 7.17% |
3,203,721
-200,000
| -6% | -$1.11M |
|
|
5
Vaxcyte
PCVX
$8.12B
| $16.9M | 6.9% |
+290,000
| New | +$15.7M |
|
6
EyePoint Inc
EYPT
$1.15B
| $13.4M | 5.48% |
1,036,737
+346,737
| +50% | +$5.18M |
|
7
X4 Pharmaceuticals
XFOR
$379M
| $13.3M | 5.44% |
3,214,766
+608,846
| +23% | +$2.28M |
|
|
8
Vor Biopharma
VOR
$1B
| $12.5M | 5.12% |
+700,000
| New | +$9.87M |
|
9
MediWound
MDWD
$183M
| $12.1M | 4.94% |
749,054
| – | – |
|
10
Verastem
VSTM
$489M
| $11.3M | 4.64% |
2,138,475
+350,000
| +20% | +$2.16M |
|
|
11
Celldex Therapeutics
CLDX
$3B
| $10.5M | 4.29% |
+330,000
| New | +$9M |
|
|
12
BioCryst Pharmaceuticals
BCRX
$2.48B
| $8.79M | 3.6% |
+923,057
| New | +$7.17M |
|
|
HELP
13
Cybin Inc
HELP
$414M
| $7.35M | 3.01% |
1,531,814
-125,726
| -8% | -$813K |
|
|
14
CG Oncology
CGON
$6.33B
| $6.77M | 2.77% |
100,000
-200,000
| -67% | -$11.3M |
|
15
InspireMD
NSPR
$33.6M
| $6.37M | 2.61% |
3,905,743
| – | – |
|
16
Atea Pharmaceuticals
AVIR
$376M
| $6.3M | 2.58% |
+1,171,855
| New | +$5.38M |
|
|
PROF
17
Profound Medical
PROF
$258M
| $5.37M | 2.2% |
828,118
-240,837
| -23% | -$1.66M |
|
18
Viridian Therapeutics
VRDN
$2.11B
| $4.9M | 2.01% |
250,401
-199,599
| -44% | -$5.93M |
|
19
PolyPid
PYPD
$103M
| $2.62M | 1.07% |
597,926
-98,630
| -14% | -$436K |
|
20
Myomo
MYO
$42.5M
| $2.6M | 1.06% |
3,847,272
+7,500
| +0.2% | +$6.15K |
|
21
Talphera
TLPH
$72.9M
| $2.51M | 1.03% |
3,353,916
-225,357
| -6% | -$204K |
|
22
Ovid Therapeutics
OVID
$459M
| $2.46M | 1.01% |
+1,107,994
| New | +$1.98M |
|
|
DFTX
23
Definium Therapeutics
DFTX
$6.1B
| $2.36M | 0.97% |
125,000
-625,000
| -83% | -$10.6M |
|
|
OKUR
24
OnKure Therapeutics
OKUR
$170M
| $1.84M | 0.75% |
443,763
-286,725
| -39% | -$885K |
|
25
Lipocine
LPCN
$19M
| $1.77M | 0.73% |
+221,616
| New | +$1.93M |
|
Similar funds
AWG
BNMT
CA
BB
GIM
IAMOG
AWM
OCFG